Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy

AIDS

Volumn 20, Issue 5, 2006, Pages 701-710

  Palmer, Sarah ^a   Boltz, Valerie ^a   Maldarelli, Frank ^a   Kearney, Mary ^a   Halvas, Elias K ^c   Rock, Diane ^b   Falloon, Judith ^b   Davey, Richard T ^b   Dewar, Robin L ^d   Metcalf, Julia A ^b   Mellors, John W ^c   Coffin, John M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

Allele specific polymerase chain reaction; HIV resistance; NNRTI resistance; Non nucleoside reverse transcriptase inhibitor; Persistence of NNRTI resistance

Indexed keywords

ADENINE; COMPLEMENTARY DNA; CYTOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMINE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG WITHDRAWAL; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTANT; PERSISTENT INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON; THERMAL ANALYSIS; VIRUS RESISTANCE; WILD TYPE;

ADULT; ALLELES; CYTOPATHOGENIC EFFECT, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; GENE FREQUENCY; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 33646481683     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000216370.69066.7f     Document Type: Article

References (46)

1. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
2. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated HIV-1 infected patients. Ann Intern Med 1998; 128:906-911.
3. Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 2004; 78:4234-4247.
4. Deeks SC, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
5. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C, et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001; 15:2189-2191.
6. Izopet J, Souyris C, Hance A, Sandres-Saune K, Alvarez M, Pasquier C, et al. Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis 2002; 185:1506-1510.
7. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, Joos B, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188:1433-1443.
8. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 1994; 47:155-169.
9. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001; 26 (Suppl 1):S25-S33.
10. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660-1666.
11. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001; 75:4999-5008.
12. Demeter L, Haubrich R. International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations. J Acquir Immune Defic Syndr 2001; 26 (Suppl 1):S3-S9.
13. Wainberg MA. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2003; 34 (Suppl 1):S2-S7.
14. Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 2001; 285:193-203.
15. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
16. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-868.
17. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-486.
18. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-846.
19. Stringer EM, Sinkala M, Stringer JS, Mzyece E, Makuka I, Goldenberg RL, et al. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS 2003; 17:1377-1382.
20. Stringer JS, Rouse DJ, Sinkala M, Marseille EA, Vermund SH, Stringer EM, et al. Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus. Lancet 2003; 362:1850-1853.
21. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228.
22. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192:24-29.
23. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23.
24. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
25. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 1998; 14:869-876.
26. Malet I, Belnard M, Agut H, Cahour A. From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. J Virol Meth 2003; 109:161-170.
27. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43:406-413.
28. Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 2002; 18:243-248.
29. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol 1998; 36:569-572.
30. Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR, et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Meth 2004; 1:141-147.
31. Shi C, Mellors JW. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother 1997; 41:2781-2785.
32. Cha RS, Zarbl H, Keohavong P, Thilly WC. Mismatch amplification mutation assay (MAMA): application to the c-H-ras gene. PCR Meth Appl 1992; 2:14-20.
33. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996; 70:7894-7899.
34. Rouzine IM, Rodrigo A, Coffin JM. Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol Mol Biol Rev 2001; 65:151-185.
35. Rouzine IM, Coffin JM. Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc Natl Acad Sci USA 1999; 96:10758-10763.
36. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucl Acids Res 2003; 31:298-303.
37. Harrigan PR, Mo T, Wynhoven B, Hirsch J, Brumme Z, McKenna P, et al. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2005; 19:549-554.
38. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18:1653-1660.
39. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14:F17-F23.
40. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683-1689.
41. Pao D, Andrady U, Clarke J, Dean C, Drake S, Fisher M, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37:1570-1573.
42. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001; 75:6410-6417.
43. Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005; 38:37-42.
44. Mellors J, Palmer S, Nissley D, Kearney M, Halvas E, Bixby C, et al. Low frequency non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes for NNRTI genotypes. Antiviral Ther 2003; 8:150.
45. Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MC, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14:F111-F115.
46. Palmer S, Boltz V, Maldarelli F, Martinson N, Gray G, McIntyre J, et al. Persistence of NNRTI-resistant variants after single-dose nevirapine in HIV-1 subtype C infected women. 12th Conference on Retroviruses and Opportunistic Infections. Boston, February 2005 [abstract 101].